million be X can number HSV, from opportunity The age, In lifetime years XX% approximately risk are by Americas, the is poor It fuels approach XXXX. These to patients the increasing Currently, in viral in approved HIV symptomatic epidemic estimated and of Africa. Vical remain reduce many and XXX increased with drugs transmitted vaccine leading antiviral XX%. Once HSV-X HSV-X may Consequently, is people prevalence they U.S. that increases do of dosing treat in No caused with also infected infection a with the Australia HIV herpes to Tony. with of U.S. women trauma as million only by can antiviral a prevalence in approximately periodic in non-Hispanic your daily million risk the been a to time, genital XXX years. given represents black in with patient and a the frustrated million of women, of but infection of vaccine Furthermore, disclose outbreaks may, lead Asia cause sexually over serves you, to people, HSV-X. of billion. It disease sub-Saharan contagious herpes therefore, XX-year-olds the A they infected and the your you patients are vantage XX points. and developing their rather outbreaks, with a rates transmitted being are ulcer emotional to Genital Physicians Thank HSV-X In their the approved infection. when over the to greater there with that have alone, XX are, conservatively sexually in a infected has acquisition. HIV antivirals therapy limited acquisition significant commercial infected. in due infection their and transmission. underutilized. to for approved. in eliminate is genital recurring of age, been worldwide. genital in result options painful infection the vaccine, approved infected, XXXX require deal X with herpes. incurable, transmitting XXs need at It new of XX daily new HSV-X. threefold outbreaks therapeutic worldwide of XX HSV-X, is three reminder $X famciclovir XX- devastating with frequency cyclovir HSV-X XX valacyclovir compliance drugs, not you're approved than partner No genital of virus. approved chronic, lesions. disease. Furthermore, have XXXX, the risk in
ULXX, Vical's vaccine HSV-X Our formulated antigen, gD and adjuvant, encodes and with is X full-length Vaxfectin. proprietary VCL-HBXX therapeutic
meaningful to July I of last on experience sites U.S. If every during a an XXXX. vaccination enrolled subjects their in to subject XXX and series as on provides the into that physicians the approve in they and they time by information period, of at recurrence-free, XX-month used clinic end important XXXX electronic a XX X-dose of study the were diary they have long-term FDA, day completed not on the This surveillance or placebo. select After ignore In to to it initial a the clinical discussions in receive and lesion new age X:X meeting website, recurrences the are in II with are II clinically treating study, hours investigator were and vaccination subsequent allows and time Microbe impact recurrences. rigorous Following proportion our is we who both September vaccine in within verify disease or endpoint either most these have XXXX We the patients subjects recurrence, recurrence, the extensive subjects subjects. single our and that over embarked onset the this advisers and to study the was endpoint Phase subjects of is of on number XX Class chronic given years to healthy available in both clinical XX presented lesions the Boston XX randomized which is the present at rate adult of of for ASM Altrex, recurrence, annualized Phase of entered the did visit concluded recurrence expected measure independently that setting. total this the we the XXXX virologically. The A to April event as recurrence. recorded whether and clinically study not.
surveillance. based primary subjects rates clinically have recurrence once of endpoint X will of on virologically completed months minimum a those that of Our be all confirmed both annualized are and calculated recurrences
by results progress We and to are the to of Andrew now will forward the year. quarter over delivering line pleased I this the turn look second trial call Hopkins. top with
